Semaglutide Safety Profile at 3 Years: What Long-Term Data Tells Us

As of mid-2026, semaglutide has been prescribed to tens of millions of patients worldwide for weight management and type 2 diabetes. The SELECT cardiovascular outcomes trial, the STEP clinical program, and extensive post-marketing surveillance now provide a clearer picture of what long-term semaglutide use looks like from a safety perspective. Here's what the data shows.

Cardiovascular Outcomes: The SELECT Trial

The landmark SELECT trial — a randomized, double-blind, placebo-controlled study of over 17,600 adults with overweight or obesity and established cardiovascular disease — provided the most significant long-term safety signal for semaglutide: a 20% reduction in major adverse cardiovascular events (MACE), including heart attack, stroke, and cardiovascular death.

This result was achieved with semaglutide 2.4 mg weekly over a median follow-up of 39.8 months (approximately 3.3 years). The cardiovascular benefit was observed regardless of whether patients had diabetes at baseline, and the risk reduction was consistent across subgroups defined by age, sex, BMI, and baseline cardiovascular risk level.

What makes this particularly noteworthy is that the cardiovascular benefit appeared to be independent of weight loss itself — patients who lost modest amounts of weight still showed cardiovascular protection. This suggests semaglutide may have direct anti-inflammatory and vascular protective effects beyond those mediated by weight reduction.

Cancer Surveillance: What the Data Shows

One of the most closely watched safety endpoints in long-term GLP-1 studies is cancer incidence. Here's what the cumulative data tells us through 3 years of follow-up:

Thyroid cancer: Despite the animal-based boxed warning, no increase in thyroid cancer (including medullary thyroid carcinoma) has been observed in human clinical trials or in large-scale epidemiological studies with over a decade of GLP-1 class exposure.

Pancreatic cancer: Initial concerns about a potential link between GLP-1 medications and pancreatic cancer have not been substantiated by long-term data. Multiple independent analyses, including a 2024 meta-analysis of over 40 randomized controlled trials, found no increased risk.

Overall cancer rates: In the SELECT trial, overall cancer incidence was numerically lower in the semaglutide group compared to placebo, though the difference was not statistically significant. This finding has generated considerable scientific interest, as obesity itself is a risk factor for multiple cancers, and whether GLP-1-mediated weight loss reduces cancer risk is an active area of investigation.

Gastrointestinal Tolerability Over Time

The GI side effect profile of semaglutide — nausea, vomiting, diarrhea, constipation — has been the most common reason for treatment discontinuation in clinical trials. But the long-term data reveals an important pattern: GI side effects are overwhelmingly front-loaded.

In the STEP 5 trial (2-year data), the vast majority of GI adverse events occurred during the first 20 weeks of treatment (the titration period). By month 6, rates of ongoing nausea, vomiting, and diarrhea dropped substantially and remained low through 2 years. Patients who made it through the titration phase experienced excellent long-term tolerability.

Discontinuation rates due to adverse events were approximately 6-7% in the STEP trials, meaning more than 93% of patients who started semaglutide were able to continue treatment. For context, discontinuation rates for many common chronic medications (statins, antihypertensives, antidepressants) are often substantially higher.

Gallbladder Events

One of the more consistent safety signals across GLP-1 studies is an increased rate of gallbladder-related events, including cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation). In the STEP trials, gallbladder events occurred in approximately 2.6% of semaglutide patients versus 1.2% on placebo.

This is not unique to semaglutide — rapid weight loss from any cause (including bariatric surgery and very low-calorie diets) increases gallstone formation risk. The mechanism is well understood: when the body rapidly metabolizes fat stores, it releases excess cholesterol into the bile, which can precipitate into stones.

Risk mitigation strategies include maintaining adequate fat intake (paradoxically, very low-fat diets increase gallstone risk by reducing gallbladder contraction), staying hydrated, and reporting right upper quadrant abdominal pain promptly.

Mental Health and Neuropsychiatric Monitoring

The FDA issued a safety review in early 2025 regarding reports of suicidal ideation in patients taking GLP-1 medications. After reviewing available data, the agency found no causal link between semaglutide and suicidal behavior but maintained that monitoring was warranted, particularly in patients with pre-existing mood disorders.

The clinical consensus as of 2026 is that significant weight loss itself can trigger complex emotional responses — including shifts in identity, relationships, and self-image — that may manifest as mood changes. Good clinical care includes screening for mood disorders at baseline and periodically during treatment, with appropriate referrals to mental health professionals when indicated.

Muscle Mass and Body Composition

One of the most discussed long-term concerns is the proportion of weight lost as lean muscle versus fat. In the STEP trials, approximately 25-40% of total weight lost was lean body mass, which is consistent with weight loss from any caloric deficit. Strategies to minimize lean mass loss include adequate protein intake (0.7-1.0 g per pound of ideal body weight), resistance training, and avoiding excessively rapid weight loss.